Clavis Pharma makes board appointments
This article was originally published in Scrip
The Norwegian cancer drug development company Clavis Pharma has elected Anders Wiklund and Annette Clancy to serve on its board of directors as chairman and non-executive director, respectively. The appointments were made at Clavis's annual general meeting held in Oslo on 20 May, when former chairman Keith McCullagh, Gert Caspritz and Stina Gestrelius also stepped down from the board. Mr Wiklund has 40 years' business and corporate development experience in the biotechnology and pharmaceutical industries. He spent 29 years with the Kabi and Pharmacia group of companies, where he served in a number of positions, including managing director of KabiVitrum (UK), president of KabiVitrum International (Sweden), and president and CEO of KabiVitrum and KabiPharmacia (US). In 1997, he founded Wiklund International, an advisory firm to the biotech industry, and co-founded Esperion Therapeutics and served for several years on its board of directors before its acquisition by Pfizer for $1.3 billion. Ms Clancy has more than 25 years' experience in the pharmaceutical industry, predominantly with GlaxoSmithKline, where she worked in a variety of functions, including R&D, strategic marketing and licensing/business development. She currently serves as a senior advisor at the US-based venture capital firm Frazier Healthcare Ventures, as chair of GSK's respiratory R&D team and as a non-executive director at Silence Therapeutics.